REVEAL AF STUDY ICM EVIDENCE FOR SUSPECTED AF

THE REVEAL AF STUDY¹

The REVEAL AF Study demonstrates the need for continuous, long-term monitoring with Reveal LINQ™ insertable cardiac monitoring (ICM) in patients at high risk for atrial fibrillation and stroke.

KEY FINDINGS

INFORM YOUR CLINICAL DECISIONS

There was no significant difference in detection rates between patients with CHADS₂ 2, 3, and 4 or more.

CLINICAL IMPACT: MORE APPROPRIATE CARE

STUDY DESIGN

• Prospective, global, multicenter study
• 446 patients enrolled, 385 patients received a Reveal™ ICM and were included in the analysis cohort
• Patients were followed for an average of 22.5 months + 7.7 months

PATIENT INCLUSION CRITERIA

• A CHADS₂ score of ≥ 3 or CHADS₂ = 2 and at least 1 of the following:
• Coronary artery disease
• Renal impairment (GFR 30-60 ml/min)
• Sleep apnea
• Chronic obstructive pulmonary disease
• No AF found after 24 hours of cardiac monitoring

END POINTS

Primary

• Determine the incidence rate of AF lasting ≥ 6 minutes in patients who are at high risk of having AF and stroke.

Secondary

• Identify predictors of AF onset
• Characterise the timing and nature of clinical actions relative to detection of AF